(Q41271542)

29 September 2017

1 reference

title

Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status (English)

1 reference

29 September 2017

1 reference

F Durand

1

1 reference

29 September 2017

G Jebrak

2

1 reference

29 September 2017

D Pessayre

3

1 reference

29 September 2017

M Fournier

4

1 reference

29 September 2017

J Bernuau

5

1 reference

29 September 2017

1 December 1996

1 reference

29 September 2017

1 reference

29 September 2017

15

1 reference

29 September 2017

6

1 reference

29 September 2017

394-405

1 reference

https://scigraph.springernature.com/pub.10.2165/00002018-199615060-00004

29 September 2017

0 references

cites work

Variations between individuals and populations in the acetylation of isoniazid and its significance for the treatment of pulmonary tuberculosis

1 reference

12 December 2020

Hepatotoxicity of rifampin and isoniazid. Is it all drug-induced hepatitis?

1 reference

12 December 2020

[Mixed hepatitis due to rifamycin SV. Apropos of a case]

1 reference

12 December 2020

Fulminant and subfulminant liver failure: definitions and causes

1 reference

12 December 2020

A controlled trial of six months chemotherapy in pulmonary tuberculosis. First Report: results during chemotherapy. British Thoracic Association

1 reference

12 December 2020

Antituberculosis treatment-induced hepatotoxicity: role of predictive factors

1 reference

12 December 2020

Toxic effects of isoniazid in tuberculosis chemoprophylaxis. Role of biochemical monitoring in 1,000 patients

1 reference

12 December 2020

Cholestatic hepatitis related to quinolones: a report of two cases

1 reference

12 December 2020

1 reference

12 December 2020

Pyrazinamide-isoniazid in tuberculosis

1 reference

12 December 2020

Acetylation phenotype and hepatotoxicity in the treatment of tuberculosis in children

1 reference

12 December 2020

Disturbed hepatic function during isoniazid chemoprophylaxis. Monitoring the hepatic function of 427 hospital employees receiving isoniazid chemoprophylaxis for tuberculosis

1 reference

12 December 2020

Fatal hepatic necrosis secondary to isoniazid therapy

1 reference

12 December 2020

Twenty isoniazid-associated deaths in one state

1 reference

12 December 2020

An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome

1 reference

12 December 2020

Acetylation rates and monthly liver function tests during one year of isoniazid preventive therapy

1 reference

12 December 2020

Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection

1 reference

12 December 2020

Isoniazid-associated hepatitis deaths: a review of available information

1 reference

12 December 2020

Six-months isoniazid-rifampin therapy for pulmonary tuberculosis. Report of a United States Public Health Service Cooperative Trial

1 reference

12 December 2020

Isoniazid-rifampin fulminant hepatitis. A possible consequence of the enhancement of isoniazid hepatotoxicity by enzyme induction

1 reference

12 December 2020

Rifampin-isoniazid therapy of alcoholic and nonalcoholic tuberculous patients in a U.S. Public Health Service Cooperative Therapy Trial

1 reference

12 December 2020

Hepatic Dysfunction During Isoniazid Chemoprophylaxis in Renal Allograft Recipients

1 reference

12 December 2020

1 reference

12 December 2020

Serum transaminase elevations and other hepatic abnormalities in patients receiving isoniazid.

1 reference

12 December 2020

1 reference

12 December 2020

Fatal hepatotoxicity of anti-tubercular chemotherapy

1 reference

12 December 2020

Toxicity form rifampicin plus isoniazid and rifampicin plus ethambutol therapy

1 reference

12 December 2020

Isoniazid-rifampin-induced hepatitis in hepatitis B carriers

1 reference

12 December 2020

Isoniazid hepatitis among pregnant and postpartum Hispanic patients

1 reference

12 December 2020

Elevated serum aminotransferase induced by isoniazid in relation to isoniazid acetylator phenotype

1 reference

12 December 2020

Tuberculosis in patients with human immunodeficiency virus infection

1 reference

12 December 2020

Rifampicin hepatitis. A clinical and histological study

1 reference

12 December 2020

[Toxicity of pyrazinamide in antituberculous treatments (author's transl)]

1 reference

12 December 2020

Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis

1 reference

12 December 2020

Cholestatic jaundice caused by ethambutol

1 reference

12 December 2020

Lack of relationship between hepatic toxicity and acetylator phenotype in three thousand South Indian patients during treatment with isoniazid for tuberculosis

1 reference

12 December 2020

Hepatotoxicity associated with acetaminophen usage in patients receiving multiple drug therapy for tuberculosis

1 reference

12 December 2020

Clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council

1 reference

12 December 2020

Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis

1 reference

12 December 2020

Hepatotoxicity due to antituberculosis therapy. Clinical profile and reintroduction of therapy

1 reference

12 December 2020

Hepatotoxicity of antituberculosis drugs

1 reference

12 December 2020

Limited tolerance of ofloxacin and pyrazinamide prophylaxis against tuberculosis

1 reference

12 December 2020

[Fulminant hepatitis induced by pyrazinamide]

1 reference

12 December 2020

Deleterious influence of pyrazinamide on the outcome of patients with fulminant or subfulminant liver failure during antituberculous treatment including isoniazid

1 reference

12 December 2020

Isoniazid-associated hepatitis in 114 patients

1 reference

12 December 2020

Isoniazid hepatoxicity: the relationship between covalent binding and metabolism in vivo

1 reference

12 December 2020

Isoniazid-associated hepatitis. Report of an outbreak

1 reference

12 December 2020

Fulminant hepatitis during treatment with rifampicin, pyrazinamid and ethambutol

1 reference

12 December 2020

Cholestatic hepatitis during treatment with I.N.H. and rifampicin: arguments in favour of the hepatotoxicity of rifampicin (author's transl)

1 reference

12 December 2020

Pyrazinamide fulminant hepatitis: an old hepatotoxin strikes again

1 reference

12 December 2020

Predisposing factors in hepatitis induced by isoniazid-rifampin treatment of tuberculosis

1 reference

12 December 2020

Toxic hepatitis with isoniazid and rifampin. A meta-analysis

1 reference

12 December 2020

Adverse Effects of Rifampin

1 reference

12 December 2020

Severe acetaminophen toxicity in a patient receiving isoniazid

1 reference

12 December 2020

10.2165/00002018-199615060-00004

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/a3hikv2eaneqbd5s6e4qzhxvvq

30 July 2022

mapped directly with Wikidata item

Dimensions Publication ID

1023649851

0 references

Fatcat ID

release_a3hikv2eaneqbd5s6e4qzhxvvq

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/a3hikv2eaneqbd5s6e4qzhxvvq

30 July 2022

mapped directly with Wikidata item

1 reference

https://api.fatcat.wiki/v0/release/a3hikv2eaneqbd5s6e4qzhxvvq

30 July 2022